

SHORT REPORT

Open Access

# Toll-like receptor 2 -196 to -174 del polymorphism influences the susceptibility of Han Chinese people to Alzheimer's disease

Jin-Tai Yu<sup>1,2†</sup>, Shan-Mao Mou<sup>1,3†</sup>, Li-Zhu Wang<sup>4</sup>, Cai-Xia Mao<sup>1,3</sup> and Lan Tan<sup>1,2\*</sup>

## Abstract

**Background:** Toll-like receptor 2 (*TLR2*) represents a reasonable functional and positional candidate gene for Alzheimer's disease (AD) as it is located under the linkage region of AD on chromosome 4q, and functionally is involved in the microglia-mediated inflammatory response and amyloid- $\beta$  clearance. The -196 to -174 del polymorphism affects the *TLR2* gene and alters its promoter activity.

**Methods:** We recruited 800 unrelated Northern Han Chinese individuals comprising 400 late-onset AD (LOAD) patients and 400 healthy controls matched for gender and age. The -196 to -174 del polymorphism in the *TLR2* gene was genotyped using the polymerase chain reaction (PCR) method.

**Results:** There were significant differences in genotype ( $P = 0.026$ ) and allele ( $P = 0.009$ ) frequencies of the -196 to -174 del polymorphism between LOAD patients and controls. The del allele was associated with an increased risk of LOAD (OR = 1.31, 95% CI = 1.07-1.60, Power = 84.9%). When these data were stratified by apolipoprotein E (*ApoE*)  $\epsilon 4$  status, the observed association was confined to *ApoE*  $\epsilon 4$  non-carriers. Logistic regression analysis suggested an association of LOAD with the polymorphism in a recessive model (OR = 1.64, 95% CI = 1.13-2.39, Bonferroni corrected  $P = 0.03$ ).

**Conclusions:** Our data suggest that the -196 to -174 del/del genotype of *TLR2* may increase risk of LOAD in a Northern Han Chinese population.

**Keywords:** Alzheimer's disease, toll-like receptor 2, polymorphism, association study

## Background

Toll-like receptor 2 (*TLR2*) represents a reasonable functional and positional candidate gene for Alzheimer's disease (AD) as it is located under the linkage region of AD on chromosome 4q [1], and is functionally involved in the microglia-mediated inflammatory response and amyloid  $\beta$  ( $A\beta$ ) clearance [2-6]. Genetic studies on the *TLR2* gene have identified a number of polymorphisms which have been shown to affect host defense, disease progression and be linked to differential disease susceptibilities [7]. We have assessed the involvement of 7 single nucleotide polymorphisms (SNPs) (Arg 677Trp,

Arg753Gln, rs1898830, rs11938228, rs3804099, rs3804100, and rs7656411) as well as a short tandem GT repeat polymorphism in intron 2 of the *TLR2* gene in the risk of developing late-onset AD (LOAD) [8,9], and found an association of GT repeat polymorphism with an increased risk for LOAD in our previous studies. A 22-bp nucleotide deletion at position -196 to -174 of the untranslated 5'-region in *TLR2* gene is associated with reduced transcriptional activity compared to the wild type allele in luciferase reporter assays [10]. This polymorphism has already been shown to be associated with an increased risk of noncardiac gastric cancer, susceptibility to cervical cancer, hepatitis C viral loads and susceptibility to hepatocellular carcinoma [11-13]. In light of the important role that TLR2 plays with respect to the immune response in the pathogenesis of AD [2-6], we hypothesized that the -196 to -174

\* Correspondence: dr.tanlan@163.com

† Contributed equally

<sup>1</sup>Department of Neurology, Qingdao Municipal Hospital, School of Medicine, Qingdao University, No.5 Donghai Middle Road, Qingdao 266071, China  
Full list of author information is available at the end of the article

del/ins polymorphism in the *TLR2* gene might be associated with AD.

## Methods

### Subjects

Our study was comprised of 400 sporadic LOAD cases (189 female and 211 male; age > 65 years; mean age = 82.8 ± 7.1 years; age at onset = 75.4 ± 5.9 years) and 400 healthy controls subjects matched for sex and age (189 female and 211 male; mean age = 81.4 ± 5.4 years). All participants originated from Northern Han Chinese populations. A clinical diagnosis of probable AD was established according to the criteria of National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's disease and Related Disorders Association (NINCDS-ADRDA) [14]. All AD cases were defined as sporadic because family histories showed no mention of first-degree relatives with dementia. Control subjects were unrelated individuals selected from the Health Examination Center of the Qingdao Municipal Hospital. These subjects were confirmed healthy and neurologically normal by complete neurological and medical examinations comprised of medical history and laboratory examinations. Written informed consent was obtained from all individuals and the study was approved by the Institute Ethical Committee.

### Genotyping

Genomic DNA was extracted from peripheral blood leukocytes using the standard method [15]. Polymorphisms at *TLR2* -196 to -174del were investigated using the polymerase chain reaction (PCR) method, following the procedures described by Tahara et al [11]. The apolipoprotein E (*ApoE*) genotype was determined according to the method described by Donohoe et al [16]. Two investigators independently reviewed all results.

### Statistical analysis

Hardy-Weinberg equilibrium was assessed using the Chi-square test. Genotype and allele distributions were

compared using the Chi-square test. Differences in allele and genotype distribution between cases and controls were analyzed using logistic regression adjusted for age and *ApoE* ε4 status under various genetic models. The Wald P value was multiplied by 3 as a Bonferroni adjustment for the 3 genetic models tested. The P value, odds ratios (OR) and 95% confidence intervals (CI) were calculated. Estimation of the statistical power was performed with the STPLAN 4.3 software. Data were analyzed using a commercially available statistical package (SPSS Version 13.0, SPSS Inc., Chicago, IL). The criterion used for significant differences is  $P < 0.05$ .

## Results

The alleles and genotypes frequencies of LOAD patients and controls in the total sample and after stratification for *ApoE* ε4 allele are given in Table 1. The distribution of genotypes of *TLR2* polymorphisms were within the range of Hardy-Weinberg equilibrium ( $P = 0.21$ ). There were significant differences in genotype and allele frequencies between LOAD and control groups (genotype  $P = 0.026$ , allele  $P = 0.009$ ). The -196 to -174 del allele significantly raised the risk of developing LOAD (OR = 1.31, 95%CI = 1.07-1.60, Power = 84.9%). In subjects without *ApoE* ε4 allele, the allele and genotype distributions between LOAD patients and controls remain significantly different (genotype  $P = 0.027$ , allele  $P = 0.009$ ). However, in subjects with the *ApoE* ε4 allele, there were no significant differences. In order to rule out confounding in our crude association analyses, we reevaluated the polymorphism effect under 3 different models using logistic regression adjusting for age and *ApoE* ε4 status (Table 2). The -196 to -174 del polymorphism was still found to increase the risk of LOAD via a recessive model (OR = 1.64, 95% CI = 1.13-2.39,  $P = 0.01$ , Bonferroni corrected  $P = 0.03$ ).

## Discussion

Many experimental and clinical studies have suggested that *TLR2* might play an important role in the

**Table 1 Distribution of the *TLR2* -196 to -174 del polymorphism in LOAD cases and controls.**

	N	Genotypes n (%)			P	Alleles n (%)		P
		ins/ins	del/ins	del/del		del	ins	
AD	400	150(37.5)	161(40.2)	89(22.2)	0.026	461(57.6)	339(42.4)	0.009
Controls	400	172(43.0)	168(42.0)	60(15.0)		512(64.0)	288(36.0)	
<i>ApoE</i> ε4(-)								
AD	260	94(36.2)	104(40.0)	62(23.8)	0.027	292(56.2)	228(43.8)	0.009
Controls	339	144(42.5)	143(42.2)	52(15.3)		431(63.6)	247(36.4)	
<i>ApoE</i> ε4(+)								
AD	140	56(40.0)	57(40.7)	27(19.3)	0.526	169(60.4)	111(39.6)	0.251
Controls	61	28(45.9)	25(41.0)	8(13.1)		81(66.4)	41(33.6)	

*ApoE* ε4 (+): subjects who carry one or two ε4 alleles; *ApoE* ε4 (-): subjects who do not carry an ε4 allele.

**Table 2 Logistic regression analysis of the -196 to -174 del polymorphism within *TLR2*.**

Model	OR (95%CI)	Wald	P	Pc
Dom	1.172(0.776-1.770)	0.568	0.451	NC
Rec	1.642(1.127-2.392)	6.669	0.010	0.030
Add	1.279(1.010-1.620)	4.179	0.041	0.123

Adjusted for age and for carriage of at least one *ApoE*  $\epsilon$ 4 allele.

Dom, dominant model: 1 (del/del+del/ins) versus 0 (ins/ins); Rec, recessive model: 1 (del/del) versus 0 (del/ins + ins/ins); Add, additive model: 0 (ins/ins) versus 1 (del/ins) versus 2 (del/del); OR, odds ratio; CI, confidence interval. Pc, corrected P for multiple testing by Bonferroni correction (P value was multiplied by 3 as a Bonferroni adjustment for the 3 genetic models tested). NC, not calculated.

pathogenesis of AD [2-6]. *TLR2* is a member of pattern-recognition receptors in the innate immune system [7]. Increased levels of *TLR2* mRNA have been found in microglia isolated from AD patients [2]. Jana et al. have supplied several lines of evidence supporting the opinion that A $\beta$  peptides activate microglia via *TLR2* as inhibition of *TLR2* through function-blocking antibodies or siRNA knockdown prevents fibrillar forms of A $\beta$  from inducing nitrite, interleukin-6 (IL-6), or tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) production [3]. Although an increasing volume of data favors *TLR2* -mediated neurotoxicity, *TLR2* may also be essential for A $\beta$  clearance and in that way provide neuroprotection in AD [4]. Reed-Geaghan et al. reported that CD14, *TLR4*, and *TLR2* are necessary for binding fibrillar A $\beta$  (fA $\beta$ ) to the cell surface, and are required for phenotypic activation of microglia and induction of phagocytosis [5]. Richard et al. demonstrated that *TLR2* deficiency in transgenic AD mice could increase A $\beta$  deposition and accelerate cognitive decline [6].

The -196 to -174 del polymorphism in the *TLR2* gene, located on chromosome 4, causes a 22 bp nucleotide deletion that alters the promoter activity of *TLR2*. The *TLR2* del/del genotype is reported to show decreased transactivation of responsive promoters [10]. Consequently, it might be speculated that expression of *TLR2* in microglial cells might exhibit low levels with the del/del genotype. Further, it can be presumed that the del/del genotype is more conducive to the occurrence of AD. Our results suggest a significant association between the -196 to -174 del allele of *TLR2* and the risk of developing LOAD in the Han Chinese population. Interestingly, this association was restricted to non-*ApoE*  $\epsilon$ 4 carriers, as no association was found for *ApoE*  $\epsilon$ 4 carriers. One possible interpretation is that the genetic effect of *TLR2* is relevant in predisposing to AD only in the absence of the *ApoE*  $\epsilon$ 4 allele, while in  $\epsilon$ 4 carriers the genetic effect is determined by this strong susceptibility factor. There is overlap in the study populations used in present study and in our previous study [9]. Linkage disequilibrium (LD)

between the GT repeat polymorphism and the -196 to -174 del polymorphism within the *TLR2* gene in the overlap study population was measured by calculating the *D'* and *r*<sup>2</sup> statistics. These were found to be in weak linkage disequilibrium (*D'* = 0.376 and *r*<sup>2</sup> = 0.009). Hence, haplotype frequencies were not estimated, and both the GT repeat and the -196 to -174 del polymorphisms might independently influence the risk of LOAD.

## Conclusions

Our data suggest that the -196 to -174 del/del genotype of *TLR2* may increase the risk of LOAD in a Northern Han Chinese population. Additional independent replications and functional genetic analyses are warranted to elucidate the potential mechanisms and the epidemiologic relevance of these associations.

## Abbreviations

A $\beta$ : amyloid  $\beta$ ; AD: Alzheimer's disease; ApoE: apolipoprotein E; CI: confidence intervals; IL-6: interleukin-6; LD: linkage disequilibrium; LOAD: late-onset AD; NINCDS-ADRDA: National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's disease and Related Disorders Association; ORs: odds ratios; PCR: polymerase chain reaction; SNPs: single nucleotide polymorphisms; TNF- $\alpha$ : tumor necrosis factor- $\alpha$ ; *TLR2*: toll-like receptor 2; TLRs: toll-like receptors; fA $\beta$ : fibrillar A $\beta$ .

## Acknowledgements

We are grateful to all of the subjects who kindly agreed to participate in this study. This work was supported by grants from the National Natural Science Foundation of China (81000544, 81171209), the Shandong Provincial Natural Science Foundation, China (ZR2010HQ004, ZR2011HZ001), the Project supported by the Qingdao Bureau of Science and Technology (10-3-3-4-19-nsh, 11-2-3-2-(1)-nsh) and the Shandong Provincial Outstanding Medical Academic Professional Program.

## Author details

<sup>1</sup>Department of Neurology, Qingdao Municipal Hospital, School of Medicine, Qingdao University, No.5 Donghai Middle Road, Qingdao 266071, China. <sup>2</sup>College of Medicine and Pharmaceutics, Ocean University of China, Qingdao 266003, China. <sup>3</sup>Taishan Medical University, Taian, Shandong Province 271016, China. <sup>4</sup>Department of VIP, Affiliated Hospital of Nantong University, Nantong, Jiangsu Province 226001, China.

## Authors' contributions

LT and JTY contributed to the design of the study. JTY, SMM, LZW, CXM and LT were involved in sample acquisition and processing. JTY, SMM, and LZW performed the statistical analyses. JTY and LT drafted the manuscript and contributed to its final version. All authors read and approved the final manuscript.

## Competing interests

The authors declare that they have no competing interests.

Received: 23 August 2011 Accepted: 11 October 2011

Published: 11 October 2011

## References

1. Blacker D, Bertram L, Saunders AJ, Moscarillo TJ, Albert MS, Wiener H, Perry RT, Collins JS, Harrell LE, Go RC, Mahoney A, Beaty T, Fallin MD, Avramopoulos D, Chase GA, Folstein MF, McInnis MG, Bassett SS, Doherty KJ, Pugh EW, Tanzi RE, NIMH Genetics Initiative Alzheimer's Disease Study Group: Results of a high-resolution genome screen of 437 Alzheimer's disease families. *Hum Mol Genet* 2003, **12**:23-32.

2. Bsibsi M, Ravid R, Gveric D, van Noort JM: (2002) **Broad expression of Toll-like receptors in the human central nervous system.** *J Neuropathol Exp Neurol* 2002, **61**:1013-1021.
3. Jana M, Palencia CA, Pahan K: **Fibrillar Amyloid- $\beta$  Peptides Activate Microglia via TLR2 Implications for Alzheimer's Disease.** *J Immunol* 2008, **181**:7254-7262.
4. Tahara K, Kim HD, Jin JJ, Maxwell JA, Li L, Fukuchi K: **Role of toll-like receptor signalling in Abeta uptake and clearance.** *Brain* 2006, **129**:3006-3019.
5. Reed-Geaghan EG, Savage JC, Hise AG, Landreth GE: **CD14 and toll-like receptors 2 and 4 are required for fibrillar A $\beta$ -stimulated microglial activation.** *J Neurosci* 2009, **29**:11982-11992.
6. Richard KL, Filali M, Préfontaine P, Rivest S: **Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid beta 1-42 and delay the cognitive decline in a mouse model of Alzheimer's disease.** *J Neurosci* 2008, **28**:5784-5793.
7. Takeda K, Kaisho T, Akira S: **Toll-like receptors.** *Annu Rev Immunol* 2003, **21**:335-376.
8. Yu JT, Sun YP, Ou JR, Cui WZ, Zhang W, Tan L: **No association of toll-like receptor 2 polymorphisms with Alzheimer's disease in Han Chinese.** *Neurobiol Aging* 2011, **32**:1924.e1-3.
9. Wang LZ, Tian Y, Yu JT, Chen W, Wu ZC, Zhang Q, Zhang W, Tan L: **Association between late-onset Alzheimer's disease and microsatellite polymorphisms in intron II of the human toll-like receptor 2 gene.** *Neurosci Lett* 2011, **489**:164-167.
10. Noguchi E, Nishimura F, Fukai H, Kim J, Ichikawa K, Shibasaki M, Arinami T: **An association study of asthma and total serum immunoglobulin E levels for Toll-like receptor polymorphisms in a Japanese population.** *Clin Exp Allergy* 2004, **34**:177-183.
11. Pandey S, Mittal RD, Srivastava M, Srivastava K, Singh S, Srivastava S, Mittal B: **Impact of Toll-like receptors [TLR] 2 (-196 to -174 del) and TLR 4 (Asp299Gly, Thr399Ile) in cervical cancer susceptibility in North Indian women.** *Gynecol Oncol* 2009, **114**:501-505.
12. Tahara T, Arisawa T, Wang F, Shibata T, Nakamura M, Sakata M, Hirata I, Nakano H: **Toll-like receptor 2 -196 to 174del polymorphism influences the susceptibility of Japanese people to gastric cancer.** *Cancer Sci* 2007, **98**:1790-1794.
13. Nischalke HD, Coenen M, Berger C, Aldenhoff K, Müller T, Berg T, Krämer B, Körner C, Odenthal M, Schulze F, Grünhage F, Nattermann J, Sauerbruch T, Spengler U: **The toll-like receptor 2 (TLR2) -196 to -174 del/ins polymorphism affects viral loads and susceptibility to hepatocellular carcinoma in chronic hepatitis C.** *Int J Cancer* 2011.
14. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: **Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.** *Neurology* 1984, **34**:939-944.
15. Blin N, Stafford DW: **A general method for isolation of high molecular weight DNA from eukaryotes.** *Nucleic Acids Res* 1976, **3**:2303-2308.
16. Donohoe GG, Salomäki A, Lehtimäki T, Pulkki K, Kairisto V: **Rapid identification of apolipoprotein E genotypes by multiplex amplification refractory mutation system PCR and capillary gel electrophoresis.** *Clin Chem* 1999, **45**:143-146.

doi:10.1186/1742-2094-8-136

**Cite this article as:** Yu et al.: Toll-like receptor 2 -196 to -174 del polymorphism influences the susceptibility of Han Chinese people to Alzheimer's disease. *Journal of Neuroinflammation* 2011 **8**:136.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
www.biomedcentral.com/submit

